Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Short Interest Up 55.4% in November

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) (TSE:CPH) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 124,000 shares, an increase of 55.4% from the October 31st total of 79,800 shares. Based on an average trading volume of 103,000 shares, the short-interest ratio is presently 1.2 days.

Cipher Pharmaceuticals Price Performance

OTCMKTS:CPHRF traded up $0.31 on Friday, reaching $10.49. The stock had a trading volume of 9,604 shares, compared to its average volume of 22,939. Cipher Pharmaceuticals has a 12-month low of $4.14 and a 12-month high of $14.60. The firm’s fifty day moving average is $11.05 and its two-hundred day moving average is $9.32.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.